User Settings
Article

Insulin glargine in a Brazilian State : an assessment of drug utilization, effectiveness and value to provide future direction

Brian Godman,Ana Luísa Caires de Souza,Francisco de Assis Acúrcio,Augusto Afonso Guerra-2014-01-01-Strathprints: The University of Strathclyde institutional repository (University of Strathclyde)
1

TL;DRAbstract

The cost and utilisation of the insulin analogue (Insulin glargine) has grown appreciably in the State of Minas Gerais in Brazil in recent years, with costs growing on average by 291% per year. This growth has been driven by an increasing number of successful law suits and a 536% price differential between insulin glargine and neutral protamine Hagedorn (NPH) insulin. One way forward to address concerns with its growing utilisation is to undertake a systematic review assessing the efficacy and safety of insulin glargine compared with NPH insulin in patients with Type I diabetes. As a result, provide published data to support future recommended activities by the State to limit its use.

Chat with Paper

AI Agents for this Paper

The cost and utilisation of the insulin analogue (Insulin glargine) has grown appreciably in the State of Minas Gerais in Brazil in recent years, with costs growing on average by 291% per year. This growth has been driven by an increasing number of successful law suits and a 536% price differential between insulin glargine and neutral protamine Hagedorn (NPH) insulin. One way forward to address concerns with its growing utilisation is to undertake a systematic review assessing the efficacy and safety of insulin glargine compared with NPH insulin in patients with Type I diabetes. As a result, provide published data to support future recommended activities by the State to limit its use.

Keywords

Insulin glargineNPH insulinInsulinMedicineProtamineDiabetes mellitusType 1 diabetesDrug

Chat

Click to start Chat